References:
1. Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma. 2010;51(11):2047-53.
2. Tchernonog E, Faurie P, Coppo P, Monjanel H, Bonnet A, Algarte Génin M, et al. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. Ann Oncol. 2017;28(4):843-8.
3. Morscio J, Dierickx D, Nijs J, Verhoef G, Bittoun E, Vanoeteren X, et al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol. 2014;38(7):875-86.
4. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin’s lymphomas. J Natl Compr Canc Netw. 2010;8(3):288-334.
5. Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010;115(15):3008-16.
6. Re A, Michieli M, Casari S, Allione B, Cattaneo C, Rupolo M, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood. 2009;114(7):1306-13.
7. Al-Malki MM, Castillo JJ, Sloan JM, Re A. Hematopoietic cell transplantation for plasmablastic lymphoma: a review. Biol Blood Marrow Transplant. 2014;20(12):1877-84.
8. Qunaj L, Castillo JJ, Olszewski AJ. Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base. Leuk Lymphoma. 2018;59(6):1375-83.
9. Schommers P, Wyen C, Hentrich M, Gillor D, Zoufaly A, Jensen B, et al. Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study. Aids. 2013;27(5):842-5.
10. Castillo JJ, Guerrero-Garcia T, Baldini F, Tchernonog E, Cartron G, Ninkovic S, et al. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol. 2019;184(4):679-82.
11. Pretscher D, Kalisch A, Wilhelm M, Birkmann J. Refractory plasmablastic lymphoma-a review of treatment options beyond standard therapy. Ann Hematol. 2017;96(6):967-70.
12. Koenig G, Stevens TM, Peker D. Plasmablastic microlymphoma arising in human herpesvirus-8-associated multicentric Castleman disease in a human immunodeficiency virus-seronegative patient with clinical response to anti-interleukin-6 therapy. Histopathology. 2015;67(6):930-2.
13. Chikeka I, Grossman M, Deng C, Jacob AT, Husain S. Plasmablastic lymphoma in an HIV patient with cutaneous presentation: A case of remarkable remission in a typically refractory disease. JAAD Case Rep. 2020;6(3):161-5.
14. Hamadani M, Devine SM. Reduced-intensity conditioning allogeneic stem cell transplantation in HIV patients with hematologic malignancies: yes, we can. Blood. 2009;114(12):2564-6.
15. Lopez A, Abrisqueta P. Plasmablastic lymphoma: current perspectives. Blood Lymphat Cancer. 2018;8:63-70.
Author Contributions: VSR and RN: conceived and lead the idea for the case report; VSR, MK and RN wrote the manuscript, contributed to the design and editing the manuscript. IA and JD contributed pathology and imaging inputs (respectively), pictures and edited the manuscript. VSR, RN, MK, SB, MR, JK, and MC: examined and treated the patient, and edited the manuscript.